vs
EXACT SCIENCES CORP（EXAS）与F5, Inc.（FFIV）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是F5, Inc.的1.1倍（$878.4M vs $811.7M），F5, Inc.净利率更高（18.2% vs -9.8%，领先28.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 11.0%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 8.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
F5, Inc.是一家美国科技企业，专注于应用安全、多云管理、线上反欺诈、应用交付网络（ADN）相关业务，同时提供应用可用性与性能优化、网络安全、访问授权管理等产品及解决方案，助力各行业客户保障数字化业务稳定运营，提升运行效率。
EXAS vs FFIV — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$811.7M
营收增速更快
EXAS
高出12.1%
11.0%
净利率更高
FFIV
高出28.0%
-9.8%
两年增速更快
EXAS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $811.7M |
| 净利润 | $-86.0M | $148.0M |
| 毛利率 | 70.1% | 81.4% |
| 营业利润率 | -9.4% | 22.1% |
| 净利率 | -9.8% | 18.2% |
| 营收同比 | 23.1% | 11.0% |
| 净利润同比 | 90.1% | 1.5% |
| 每股收益（稀释后） | $-0.45 | $2.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFFIV
| Q1 26 | — | $811.7M | ||
| Q4 25 | $878.4M | $822.5M | ||
| Q3 25 | $850.7M | $810.1M | ||
| Q2 25 | $811.1M | $780.4M | ||
| Q1 25 | $706.8M | $731.1M | ||
| Q4 24 | $713.4M | $766.5M | ||
| Q3 24 | $708.7M | $746.7M | ||
| Q2 24 | $699.3M | $695.5M |
净利润EXASFFIV
| Q1 26 | — | $148.0M | ||
| Q4 25 | $-86.0M | $180.1M | ||
| Q3 25 | $-19.6M | $190.5M | ||
| Q2 25 | $-1.2M | $189.9M | ||
| Q1 25 | $-101.2M | $145.5M | ||
| Q4 24 | $-864.6M | $166.4M | ||
| Q3 24 | $-38.2M | $165.3M | ||
| Q2 24 | $-15.8M | $144.1M |
毛利率EXASFFIV
| Q1 26 | — | 81.4% | ||
| Q4 25 | 70.1% | 81.5% | ||
| Q3 25 | 68.6% | 82.2% | ||
| Q2 25 | 69.3% | 81.0% | ||
| Q1 25 | 70.8% | 80.7% | ||
| Q4 24 | 69.0% | 81.7% | ||
| Q3 24 | 69.4% | 80.8% | ||
| Q2 24 | 69.8% | 80.4% |
营业利润率EXASFFIV
| Q1 26 | — | 22.1% | ||
| Q4 25 | -9.4% | 26.0% | ||
| Q3 25 | -3.0% | 25.4% | ||
| Q2 25 | -0.3% | 25.2% | ||
| Q1 25 | -13.6% | 21.7% | ||
| Q4 24 | -122.8% | 26.8% | ||
| Q3 24 | -5.6% | 25.6% | ||
| Q2 24 | -3.8% | 23.4% |
净利率EXASFFIV
| Q1 26 | — | 18.2% | ||
| Q4 25 | -9.8% | 21.9% | ||
| Q3 25 | -2.3% | 23.5% | ||
| Q2 25 | -0.1% | 24.3% | ||
| Q1 25 | -14.3% | 19.9% | ||
| Q4 24 | -121.2% | 21.7% | ||
| Q3 24 | -5.4% | 22.1% | ||
| Q2 24 | -2.3% | 20.7% |
每股收益（稀释后）EXASFFIV
| Q1 26 | — | $2.58 | ||
| Q4 25 | $-0.45 | $3.10 | ||
| Q3 25 | $-0.10 | $3.25 | ||
| Q2 25 | $-0.01 | $3.25 | ||
| Q1 25 | $-0.54 | $2.48 | ||
| Q4 24 | $-4.69 | $2.82 | ||
| Q3 24 | $-0.21 | $2.79 | ||
| Q2 24 | $-0.09 | $2.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.6B |
| 总资产 | $5.9B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASFFIV
| Q1 26 | — | $1.4B | ||
| Q4 25 | $964.7M | $1.2B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $858.4M | $1.4B | ||
| Q1 25 | $786.2M | $1.3B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.1B | ||
| Q2 24 | $946.8M | $935.6M |
股东权益EXASFFIV
| Q1 26 | — | $3.6B | ||
| Q4 25 | $2.4B | $3.5B | ||
| Q3 25 | $2.5B | $3.6B | ||
| Q2 25 | $2.5B | $3.5B | ||
| Q1 25 | $2.4B | $3.3B | ||
| Q4 24 | $2.4B | $3.2B | ||
| Q3 24 | $3.2B | $3.1B | ||
| Q2 24 | $3.2B | $3.0B |
总资产EXASFFIV
| Q1 26 | — | $6.5B | ||
| Q4 25 | $5.9B | $6.3B | ||
| Q3 25 | $5.9B | $6.3B | ||
| Q2 25 | $5.8B | $6.1B | ||
| Q1 25 | $5.7B | $5.9B | ||
| Q4 24 | $5.9B | $5.9B | ||
| Q3 24 | $6.7B | $5.6B | ||
| Q2 24 | $6.7B | $5.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $525.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 3.55× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASFFIV
| Q1 26 | — | $525.1M | ||
| Q4 25 | $151.7M | $159.2M | ||
| Q3 25 | $219.9M | $208.1M | ||
| Q2 25 | $89.0M | $282.2M | ||
| Q1 25 | $30.8M | $256.6M | ||
| Q4 24 | $47.1M | $202.8M | ||
| Q3 24 | $138.7M | $246.5M | ||
| Q2 24 | $107.1M | $159.0M |
自由现金流EXASFFIV
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $149.5M | ||
| Q3 25 | $190.0M | $191.9M | ||
| Q2 25 | $46.7M | $273.7M | ||
| Q1 25 | $-365.0K | $246.1M | ||
| Q4 24 | $10.7M | $194.7M | ||
| Q3 24 | $112.6M | $240.4M | ||
| Q2 24 | $71.2M | $153.1M |
自由现金流率EXASFFIV
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 18.2% | ||
| Q3 25 | 22.3% | 23.7% | ||
| Q2 25 | 5.8% | 35.1% | ||
| Q1 25 | -0.1% | 33.7% | ||
| Q4 24 | 1.5% | 25.4% | ||
| Q3 24 | 15.9% | 32.2% | ||
| Q2 24 | 10.2% | 22.0% |
资本支出强度EXASFFIV
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 1.2% | ||
| Q3 25 | 3.5% | 2.0% | ||
| Q2 25 | 5.2% | 1.1% | ||
| Q1 25 | 4.4% | 1.4% | ||
| Q4 24 | 5.1% | 1.1% | ||
| Q3 24 | 3.7% | 0.8% | ||
| Q2 24 | 5.1% | 0.8% |
现金转化率EXASFFIV
| Q1 26 | — | 3.55× | ||
| Q4 25 | — | 0.88× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 1.49× | ||
| Q1 25 | — | 1.76× | ||
| Q4 24 | — | 1.22× | ||
| Q3 24 | — | 1.49× | ||
| Q2 24 | — | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FFIV
暂无分部数据
